Transplacental Transfer of Hepatitis B Neutralizing Antibody during Pregnancy in an Animal Model : Implications for Newborn and Maternal Health

Abstract EN

Despite the success of postexposure prophylaxis (PEP) of the newborn in preventing mother-to-child transmission of hepatitis B virus), in non-US clinical trials, administering hepatitis B immune globulin (HBIG) to mothers at the end of pregnancy (in addition to passive-active PEP of the newborn) only partially improved outcomes.

That is, a significant percentage of newborns became infected during their first year of life.

We used a relevant animal model for human IgG transplacental transfer to study dose, time and subclass dependence of HBV neutralizing antibody (nAb) maternal, and fetal levels at the end of pregnancy.

Pregnant guinea pigs received 50 or 100 IU/kg HBIGIV 2–5 days before delivery.

Human total IgG, IgG subclasses, and nAb in mothers and their litters were measured.

In vitro analyses of guinea pig Fc neonatal receptor binding to HBIGIV, as well as to all human IgG subclasses, were also performed.

Our study showed that nAb transferred transplacentally from the pregnant guinea pigs to their litters; no transfer occurred during parturition.

The amount of the transferred nAb was dose and time dependent.

Thus, selection of an efficacious dose in the clinic is important: microdosing may be underdosing, particularly in cases of high viraemia.